Under the FY2027 Hospice Final Rule (CMS-1851-F), CMS introduced a new tool that puts a single number on every Medicare-certified hospice in the country: the Service and Spending Variation Index, or SSVI. For the first time, hospices can see — in black and white, published by CMS — how their claims patterns compare to their peers nationally.
This article walks through what the SSVI measures, why non-hospice spend sits at the center of it, how to check where your hospice stands today, and what a layered approach to managing that spend actually looks like.
The SSVI Matrix: Two Scores, One Index
The SSVI runs on a 0–16 scale, built from nine claims-based measures and split into two components:
Non-Hospice Spending Score (0–8) — Medicare spending occurring outside the hospice benefit for a hospice’s enrolled patients. In plain terms: are a hospice’s patients’ drugs and services showing up on Part D and other claims that CMS believes should be flowing through hospice instead?
Utilization Score (0–8) — outlier patterns across service-delivery indicators like length of stay, live discharge rates, and end-of-life visit intensity.
A high score isn’t a fraud finding. But CMS has been explicit that it’s a signal for “additional targeted education and oversight” — and the scores are now public, hospice by hospice.
The common thread across both halves of the matrix is visibility. Hospices that can’t clearly show what’s being prescribed, why it’s related (or not) to the terminal diagnosis, and how formulary decisions are governed are the ones most exposed when a high SSVI score invites a closer look.
The Non-Hospice Spending Score: What It’s Really Measuring
The Non-Hospice Spending Score runs 0–8, scored across eight spending tiers based on Medicare spending occurring outside the hospice benefit for a hospice’s enrolled patients.
Non-Hospice Spending Score — 8 Tiers (FY2025 data)
| Points | Annual Non-Hospice Spending |
| 0 | $0 (no reported non-hospice spending) |
| 1 | Greater than $0, up to $6,352.84 |
| 2 | Greater than $6,352.84, up to $20,612.10 |
| 3 | Greater than $20,612.10, up to $42,911.79 |
| 4 | Greater than $42,911.79, up to $76,801.05 |
| 5 | Greater than $76,801.05, up to $133,440.80 |
| 6 | Greater than $133,440.80, up to $246,123.10 |
| 7 | Greater than $246,123.10, up to $517,204.40 |
| 8 | Greater than $517,204.40 |
CMS has said it plainly since 1983: “virtually all” of a terminally ill patient’s care should be provided by the hospice. So, when Part D or other Medicare claims show up for a hospice patient, CMS reads that as a gap — either a missed relatedness determination, a formulary decision that quietly shifted cost elsewhere, or a drug that should have been covered and billed through the hospice benefit in the first place.
The uncomfortable part is that hospices don’t always know this is happening until the score is published. Medications get filled outside the hospice’s line of sight, relatedness gets judged inconsistently across the IDG, and spending drifts to Part D without a documented reason why.
This is exactly why the relatedness-determination and formulary-governance side of PBM work matters so much right now. When every medication runs through one platform, and every non-formulary decision has a documented rationale behind it, that spending doesn’t drift — and if CMS does ask, the paper trail is already there.
The Utilization Score: A Care-Delivery Story, Not a Pharmacy One
The Utilization Score is the second component of the SSVI. It runs 0–8, with one point added for each of eight care-delivery patterns a hospice trips:
- No Continuous Home Care or General Inpatient Care provided all year
- 40%+ of Routine Home Care days delivered in a nursing home or SNF
- Skilled visits in the final two days of life at or below 87.5%
- Live discharge rate at or above 33.3%
- Long length-of-stay discharges (180+ days) at or above 46.7%
- Average skilled nursing minutes per RHC day at or below 9.9
- Weekend RHC days with a skilled visit at or below 4.8%
- Live discharges that return to the same hospice within 7 days at or above 18.2%
Most of these thresholds sit at the 25th or 75th percentile nationally — this isn’t a fixed clinical bar; it’s a peer-comparison model. Tripping one flag may mean nothing; tripping several is what CMS reads as a pattern worth a closer look.
Unlike the spending side of the SSVI, none of these eight flags are about what’s being prescribed — they’re about visit intensity, discharge timing, and level-of-care decisions made by the IDG day to day. That makes the Utilization Score harder to manage from a single system, and it’s a good reminder that SSVI exposure isn’t only a pharmacy problem. It’s an operations and documentation problem across the whole care team.
How to Check Where Your Hospice Stands
Hospices don’t have to wait for a CMS audit to find out how much non-hospice spend their patients are generating. The data already exists — most just haven’t gone looking yet. Here’s where to look:
Your published SSVI score: CMS’s Hospice Center page includes the Non-Hospice Spending Score and Utilization Score for nearly every Medicare-certified hospice, calculated from FY2024 and FY2025 claims data. Pulling that file is step one.
Your PS&R Report 810: This is the source-of-truth report behind several SSVI measures: Medicare days, visit units, RN intensity, and length of stay. It won’t show non-hospice spending directly, but it’s the baseline needed to understand utilization patterns before comparing them to CMS’s thresholds.
Part B and Part D claims for your census: Non-hospice spend shows up as Medicare paying for drugs, procedures, or services outside the per-diem while a patient is on hospice election. This is the hardest data to see without help, since it lives outside a hospice’s own billing system.
Your PBM’s utilization reporting: This is where a documentation and reporting partner earns its keep. NaviScript’s standard reports flag high-cost medications, high-cost patients, non-formulary drugs, and branded medications by patient, on an ongoing basis — surfacing the same signals CMS is scoring on before the file gets published.
None of these sources alone give the full picture. Together, they show where exposure is coming from, and whether it’s a formulary gap, a documentation gap, or a genuine outlier in care patterns worth reviewing with the IDG.
Managing Non-Hospice Spend: Beyond Formulary Management
Reducing non-hospice spend isn’t a formulary problem. It’s a formulary problem plus three others. A strong formulary alone won’t move the number by itself — closing the gap takes four layers working together.
Formulary Management: A custom formulary that guides coverage decisions, favorite medications and order sets built around a hospice’s preferences, and continual drug utilization review to keep it current.
Clinical Guidance: Direct guidance on high-cost and high-utilization medications, ongoing deprescribing support as patients progress, and therapeutic alternatives identified before costs escalate.
Clinical Support (PharmD): Personalized pharmacist services for complex pharmacotherapy needs, comprehensive drug utilization review, and 24/7 support to resolve rejections before they become denials.
Education: Accredited, hospice-specific continuing education for clinical staff, plus a dedicated account team providing hands-on training and frequent touchpoints.
Formulary rules can only catch so much. It’s the guidance behind the rules, the pharmacist reviewing the hard cases, and the ongoing education for the IDG that actually change prescribing behavior — and that’s what shows up as a lower non-hospice spend number over time.
The Bottom Line
The SSVI isn’t going away, and CMS has made clear it plans to calculate it every fiscal year using that year’s claims data. The hospices in the strongest position won’t be the ones scrambling to explain a high score after the fact — they’ll be the ones that already built the visibility, documentation, and clinical support to keep that score low in the first place. That’s the model NaviScript is built on: not just a formulary, but the support system around it.
Sources & Further Reading
CMS Fact Sheet — Fiscal Year 2027 Hospice Wage Index and Payment Rate Update, Hospice Quality Reporting Program Requirements (CMS-1851-F)** https://www.cms.gov/newsroom/fact-sheets/fiscal-year-2027-hospice-wage-index-payment-rate-update-hospice-quality-reporting-program
SSVI Scores and Methodology — Federal Register** https://www.federalregister.gov/d/2026-15686
CMS Hospice Center — SSVI Scores and Data** https://www.cms.gov/medicare/enrollment-renewal/providers-suppliers/hospice-center
CMS Provider Statistical & Reimbursement (PS&R) System Overview** https://www.cms.gov/medicare/audits-compliance/part-a-cost-report/provider-statistical-reimbursement-report-psr